Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer

Enzalutamide, an androgen receptor inhibitor, has been clinically approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the United States. However, patients only benefit from enzalutamide for a short period of time as resistance may develop. Therefore, it is vital t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaoliang, Yin, Lili, Qiao, Gan, Li, Yanhua, Li, Baoyuan, Bai, Yunfeng, Feng, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400968/
https://www.ncbi.nlm.nih.gov/pubmed/32782617
http://dx.doi.org/10.3892/ol.2020.11823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400968/
https://www.ncbi.nlm.nih.gov/pubmed/32782617
http://dx.doi.org/10.3892/ol.2020.11823

Ejemplares similares